AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie rinvoq (upadacitinib) — International net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, Q2 2026
760
Period ended Jun 30, 2026
Change on a year earlier
+31.9%
576 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up rinvoq (upadacitinib) — international net revenues ($m)
Cite this data
StockData. (2026). AbbVie Rinvoq (upadacitinib) — International net revenues ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rinvoq_intl
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.